> top > docs > PubMed:15264243 > annotations

PubMed:15264243 JSONTXT

Annnotations TAB JSON ListView MergeView

DisGeNET

Id Subject Object Predicate Lexical cue
T0 784-787 gene:3569 denotes HGF
T1 805-820 disease:C0376358 denotes prostate cancer
T2 784-787 gene:3569 denotes HGF
T3 805-820 disease:C0600139 denotes prostate cancer
T4 784-787 gene:6654 denotes HGF
T5 805-820 disease:C0376358 denotes prostate cancer
T6 784-787 gene:6654 denotes HGF
T7 805-820 disease:C0600139 denotes prostate cancer
T8 784-787 gene:3082 denotes HGF
T9 805-820 disease:C0376358 denotes prostate cancer
T10 784-787 gene:3082 denotes HGF
T11 805-820 disease:C0600139 denotes prostate cancer
R1 T0 T1 associated_with HGF,prostate cancer
R2 T2 T3 associated_with HGF,prostate cancer
R3 T4 T5 associated_with HGF,prostate cancer
R4 T6 T7 associated_with HGF,prostate cancer
R5 T8 T9 associated_with HGF,prostate cancer
R6 T10 T11 associated_with HGF,prostate cancer

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
15264243-0#14#29#gene4233 14-29 gene4233 denotes HGF/SF receptor
15264243-0#117#132#diseaseC0376358 117-132 diseaseC0376358 denotes prostate cancer
15264243-0#117#132#diseaseC0600139 117-132 diseaseC0600139 denotes prostate cancer
15264243-5#14#17#gene3082 784-787 gene3082 denotes HGF
15264243-5#35#50#diseaseC0376358 805-820 diseaseC0376358 denotes prostate cancer
15264243-5#35#50#diseaseC0600139 805-820 diseaseC0600139 denotes prostate cancer
14#29#gene4233117#132#diseaseC0376358 15264243-0#14#29#gene4233 15264243-0#117#132#diseaseC0376358 associated_with HGF/SF receptor,prostate cancer
14#29#gene4233117#132#diseaseC0600139 15264243-0#14#29#gene4233 15264243-0#117#132#diseaseC0600139 associated_with HGF/SF receptor,prostate cancer
14#17#gene308235#50#diseaseC0376358 15264243-5#14#17#gene3082 15264243-5#35#50#diseaseC0376358 associated_with HGF,prostate cancer
14#17#gene308235#50#diseaseC0600139 15264243-5#14#17#gene3082 15264243-5#35#50#diseaseC0600139 associated_with HGF,prostate cancer

PubMed_Structured_Abstracts

Id Subject Object Predicate Lexical cue
T1 152-596 BACKGROUND denotes Hepatocyte growth factor scatter factor (HGF/SF) elicits a number of biological activities including invasion and migration through activation of its tyrosine kinase receptor c-Met. Over expression of c-Met has been implicated in prostate cancer development and progression. This study examined the effect of a ribozyme transgene, designed to inhibit human c-Met expression, and its impact on in vitro invasion and migration in prostate cancer.
T2 606-901 METHODS denotes A transgene (Met 560) consisting of U1 snRNA, hammerhead ribozyme, and antisense was cloned into a modified pZeoU1-EcoSpe vector and transfected into DU-145 cells. The effect of HGF/SF was tested on prostate cancer cells whose expression of c-Met had been blocked by way of a ribozyme transgene.
T3 911-1776 RESULTS denotes Met 560 stable transfectants (DU-145(+/+)) manifested a complete loss of c-Met expression at mRNA and protein levels. In contrast, control plasmid (DU-145(+/-)) and wild-type DU-145 cells (DU-145(-/-)) had similar levels of c-Met expression. HGF/SF significantly increased the in vitro invasiveness (mean 47.71 +/- SE 7.75; P < 0.01 vs. control 24.14 +/- 1.34), and migration (mean 48.44 +/- SE 3.51; P < 0.01 vs. control 22.95 +/- 1.47) of DU-145(-/-) cells, respectively. Similarly, HGF/SF also increased the invasion (62.33 +/- 6.34; P < 0.001 vs. control 24.5 +/- 2.35) and migration (46.14 +/- 2.26; P < 0.01 vs. control 21.82 +/- 1.62) of DU-145(+/-) cells. In contrast, DU-145(+/+) cells had lost its response to HGF/SF induced invasion (22.33 +/- 2.08; P > 0.05 vs. control 23.5 +/- 2.11) and migration (24.12 +/- 0.86; P > 0.05 vs. control 23.27 +/- 0.81).
T4 1790-2018 CONCLUSIONS denotes Targeting the HGF/SF receptor by way of a hammerhead ribozyme encoding antisense to c-Met, is an effective method to reduce the invasive or migration potential in prostate cancer, and may have important therapeutic implications.